Healthcare R&D
Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis to infertility. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more
Biopharmaceuticals
Biopharmaceuticals
Life Science R&D
R&D focus: Reimagining new ways to meet the needs of our customers
Innovation is at the core of the value that we deliver to our customers. Our Life Science business is research driven and innovation focused. In 2016, we invested 260 million Euro in R&D which supported our innovation in launching 2,100 products – products designed to meet our customers' most unmet needs – from antibodies to water purification systems.
The ability to innovate is the core of our culture across all three of our businesses; Research Solutions, Process Solutions and Applied Solutions. Learn more
Performance Materials R&D
R&D focus: Keeping the world’s performance materials on the cutting edge
Our performance materials business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more
Related News
View All News-
Press Releases
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New ...
Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono, Inc. in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the..
2020/09/18
-
Press Releases
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment ...
Merck KGaA, Darmstadt, Germany, today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the new drug application (NDA) for once-daily, orally-dosed tepotinib*
2020/08/25
-
Press Releases
NICE Recommends BAVENCIO® (Avelumab) in Combination with Axitinib ...
This is the first combination of an immunotherapy with a targeted antiangiogenic therapy to be recommended by NICE as a first-line treatment option for aRCC for use within the Cancer Drugs Fund.
2020/07/31
Healthcare R&D
Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis and infertility to colds and pains. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more